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OUTCOME FOLLOWING UNRELATED CORD BLOOD TRANSPLANT IN
136 PATIENTS WITH MALIGNANT AND NON-MALIGNANT DISEASES: A
REPORT FROM THE AUSTRALIAN AND NEW ZEALAND CHILDREN’S
HAEMATOLOGY AND ONCOLOGY GROUP (ANZCHOG)
Petterson, T.E.1, Tiedemann, K.2, Teague, L.3, Shaw, P.J.4, Baker, D.5,
Bolton-Jones, R.6, Oswald, C.1, O’Brien, T.A.1 1Centre for Children’s
Cancer & Blood Disorders, Sydney Children’s Hospital, Sydney, New
South Wales, Australia; 2The Royal Children’s Hospital, Melbourne,
Melbourne, Victoria, Australia; 3Starship Hospital, Auckland, North
Island, New Zealand; 4The Children’s Hospital at Westmead, Sydney,
New South Wales, Australia; 5Princess Margaret Hospital, Perth, West-
ern Australia, Australia; 6The Royal Children’s Hospital, Brisbane,
Brisbane, Queensland, Australia.
Unrelated cord blood (UCB) is an alternate stem cell source for
patients lacking matched family donors. Speed of availability, tol-
erance of HLA disparity, reduced acute GVHD and reduced risk of
viral disease transmission are advantages of UCB over unrelated
bone marrow. We report the results of all unrelated UCB trans-
plants performed in Australasian paediatric HSCT centres over the
last 10 years. Between April 1995 and July 2005, 136 patients were
transplanted for malignant (n  101; 74%) and non-malignant
(n  33) diseases. Log-rank tests and Cox regression analysis were
used to determine the effects of demographic, graft-related and
treatment factors on engraftment, GVHD, TRM and survival.
Median follow-up for surviving patients is 19 months (range,
1-108). The median age and weight of recipients is 5.1 years
(range, 0.2 to 18) and 19 kg (range, 7 to 101), respectively. Median
infused total nucleated cell (TNC) dose was 4.6  107 NC/kg
(range, 0.7-49.9) and median infused CD34 cell dose was 1.9 
105/kg (range, 0.1-33). 16% of patients received a 6/6 HLA-
matched unit, 44% a 5/6, 39% a 4/6 and 1 patient received a 3/6
HLA-matched unit. The incidence of neutrophil recovery by day
42 was 0.82 (95% [CI], 0.75-0.89) with a median time of 23 days
(range, 10-55) to achieve engraftment (deﬁned as ANC 0.5 
109/L). The incidence of platelet recovery by day 60 was 0.46 (CI,
0.37-0.55) with a median time of 47 days to achieve a platelet
count  20  109/L. Incidences of grades II-IV and III-IV acute
GVHD were 0.41 (CI, 0.32-0.5) and 0.18 (95% CI, 0.10-0.26),
respectively. TRM and survival at 1-year post transplant was 0.31
(CI, 0.23-0.39) and 0.62 (CI, 0.54-0.70), respectively. Leukaemic
relapse at 2 years was 0.23 (CI, 0.12-0.34). In Cox regression
analysis, time to engraftment was consistently the only factor
identiﬁed to be of signiﬁcance. Time to engraftment was signiﬁ-
cantly faster when the infused CD34 dose was 	1.7  105/kg (P 
.001) (median 18 days (CI 16-20) vs. 26 days (CI 22-29). A TNC
dose	3.0 107/kg was associated with higher overall engraftment
rates but had no signiﬁcant impact on speed of engraftment (P 
.08). This large paediatric series conﬁrms that unrelated UCB is a
viable stem cell source and that higher CD34 cell doses results in
a signiﬁcantly faster time to engraftment.
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BONE MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA
Santarone, S., Olioso, P., Di Bartolomeo, E., Bavaro, P., Papalinetti, G.,
Di Carlo, P., Di Bartolomeo, P. Department of Hematology, Bone
Marrow Transplant Center, Pescara, Italy.
In this study we report the long-term results of bone marrow
transplantation (BMT) in 113 patients (M 56, F 57) with thalasse-
mia major (TM) who were given 117 transplants from HLA iden-
tical sibling donor between May 1983 and September 2005. The
median age was 9.09 years (0.11-28.11). The median number of
transfusions given before BMT was 136 (2-900). The pretransplant
liver biopsy performed in 78 patients showed: chronic persistent
hepatitis in 35, mild chronic active hepatitis (CAH) in 10, moderate
CAH in 23, severe CAH in 10. All patients received the same
preparative therapy consisting of busulphan (BU) (13-14 mg/kg)
and cyclophosphamide (200 mg/kg), preceded by an hypertransfu-
sion regimen for 2-3 weeks. For graft-versus-host disease (GvHD)
prophylaxis, 38 patients were given cyclosporine (CSA) alone and
75 received CSA and short course methotrexate. The median
number of transplanted nucleated cells was 4.8 108/kg (2.3-10.1).
Marrow engraftment was evident in 111 patients. The median time
to achieve 0.5 109/L neutrophils and 50 109/L platelets was 19
(11-37) and 24 (10-55) days respectively. Four patients had an
autologous reconstitution and are currently alive under transfusion
therapy. The probability of graft rejection was 6.6%. The actuarial
probability of developing acute GvHD grade II-IV and cumulative
chronic GvHD was 21% and 17% (7% limited, 10% extensive)
respectively. Transplant related mortality was 8.8%. Ten patients
died for BMT related causes: pneumonia in 4, heart failure in 3,
encephalopathy in 2, aGvHD in 1. Two late deaths occurred, one
for septic shock 54 months post-BMT and one for parotitis carci-
noma 138 months after BMT. As of October 2005, 101 patients are
alive and 97 of them are cured after a median follow-up of 158
months (1-269). The 10-year actuarial probability of survival and
disease-free survival (DFS) was 91% and 87% respectively. In
multivariate analysis, no adverse risk factor affecting survival and
DFS was identiﬁed among recipient-donor age and sex, number of
pre-BMT transfusions, level of ferritin, type of CAH, grade of liver
ﬁbrosis, serum GPT level, HBV and HCV serology, dose of BU,
type of GvHD prophylaxis, marrow cell dose. This study conﬁrms
the feasibility of curing the majority of patients with TM by BMT.
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A SELECTABLE BICISTRONIC RETROVIRAL VECTOR CORRECTS THE
MOLECULAR DEFECT IN A CELL LINE DERIVED FROM A PATIENT WITH
LEUKOCYTE ADHESION DEFICIENCY
Sokolic, R.A.1, Bauer, T.R.1, Tuschong, L.M.1, Rasmussen, R.M.1,
Lanar, S.1,2, Hickstein, D.D.1 1Experimental Transplantation and Im-
munology Branch, National Cancer Institute, Bethesda, MD; 2ORWH-
NIH-FAES Summer Research Program for High School Students,
Bethesda, MD.
Leukocyte adhesion deﬁciency (LAD) is an immunodeﬁciency
disease resulting from defects in the integrin CD18. Children
with LAD suffer severe, recurrent bacterial infections due to
failure of leukocytes to adhere to endothelium and migrate to
sites of infection. Approximately 75% of severe LAD patients
die by two years of age. Allogeneic hematopoietic stem cell
transplant after myeloablation can cure LAD, however regimen-
related toxicity and graft-vs.-host disease (GvHD) limit the use
of this approach. Genetic correction of autologous CD34 cells
represents an optimal therapy for LAD since no donor is re-
quired, nor is GvHD a risk. In this study we developed a
retroviral vector that confers a selectable growth advantage for
pre-clinical testing of gene therapy in the canine model of LAD
(CLAD). This retroviral vector allows for correction of the
CD18 defect in CLAD and selection of the corrected cells. The
vector, MSCV(cCD18)IRES-cMGMTP144K, harbors the ca-
nine CD18 cDNA followed by an internal ribosome entry site
(IRES) for expression of mutated canine methylguanine meth-
yltransferase (MGMT). Mutant MGMT confers resistance to
the combination of carmustine (BCNU) and O6-benzylguanine
(BG). A high-titer producer line was identiﬁed using the PG13
packaging line, and supernatant from this producer line was
used to transduce an EBV-transformed B cell line derived from
a CD18- LAD patient. Transduced and mock-transduced cells
were grown in 25 M BG and increasing concentrations of
BCNU. In one experiment, 5 M BCNU  25 M BG allowed
selection of CD18 cells to 	 99% purity, however a distinct
CD18- population remained. In a second experiment, cells se-
lected in 10 M BCNU  25 M BG were  99.9% CD18
with no distinct CD18 population. These studies demonstrate
that a bicistronic retroviral vector leads to selection of a popu-
lation of molecularly corrected LAD cells. Selection was
achieved despite placement of MGMT after the IRES, where
expression of the selectable gene product is expected to be
decreased. Experiments with CD34 cells from CLAD dogs
will allow this approach to be tested in vivo. These studies
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demonstrate that mutant MGMT after an IRES facilitates the
selection of cells expressing a gene that is therapeutic for a
human disease. This model should be useful for gene therapy of




EUROPEAN EXPERIENCE OF ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION FOR METASTATIC RENAL CARCINOMA: ON
BEHALF OF THE FRENCH ITAC GROUP AND THE EBMT SOLID
TUMOUR WORKING PARTY
Barkholt, L.1, Bregni, M.2, Remberger, M.1, Blaise, D.3,
Peccatori, J.2, Massenkeil, G.4, Pedrazzoli, P.5, Zambelli, A.6,
Bay, J.-O.7, Francois, S.8, Martino, R.9, Bengala, C.10,
Brune, M.11, Lenhoff, S.12, Porcellini, A.13, Falda, M.14, Siena, S.5,
Demirer, T.15, Niederwieser, D.16, Ringden, O.1 1Karolinska Uni-
versity Hospital, Stockholm, Sweden; 2Istituto Scientiﬁco H.S. Raf-
faele, Milan, Italy; 3Institut Paoli Calmettes, Marseille, France;
4Hospital Charite´, Berlin, Germany; 5Ospedale Niguarda Ca
Granda, Milan, Italy; 6Fondazione S. Maugeri, Pavia, Pavia, Italy;
7Centre Jean Perrin-CHU, Clermont Ferrand, France; 8CHRU,
Angers, France; 9Hospital Santa Creu I Sant Pau, Barcelona, Spain;
10St. Chiara University Hospital, Pisa, Italy; 11Sahlgrenska Univer-
sity Hospital, Gothenburg, Sweden; 12Lund University Hospital,
Lund, Sweden; 13Departimento di Oncologia/Ematologia, Ospedale
P.F., Calvi Noale, Italy; 14Azienda Ospedaliera S. Giovanni, Torino,
Italy; 15Ankara University Medical School, Ankara, Turkey; 16Uni-
versity Hospital Leipzig, Leipzig, Germany.
The immunological graft-versus-tumor (GVT) effect has been
reported in various solid cancers after allogeneic hematopoietic
stem cell transplantation (HSCT). We evaluated the experience
of allogeneic HSCT for renal cell carcinoma (RCC) in Europe.
Methods and Patients: We report the data on 124 patients
with clear cell RCC, median age 52 years (range 18-68) trans-
planted in 21 European centers. Various reduced intensity con-
ditionings (RIC) based on ﬂudarabine were used. All patients
received allogeneic peripheral blood cells: 106 from an HLA-
identical sibling, 5 from mismatched related donor and 13 from
matched unrelated donor (MUD). GVHD prophylaxis consisted
of cyclosporine A (CyA) alone, or combined with methotrexate
or mycophenolate mofetil. All patients with mismatch or MUD
received anti-T-lymphocyte immunoglobulin. Donor lympho-
cyte infusions (DLI) were given to 42 patients. The median
follow-up was 15 months (range 3-41). Results: All but 3
patients engrafted. The cumulative incidence of grades II-IV
acute graft-versus-host disease (GVHD) was 40% and for
chronic GVHD it was 33%. Transplant-related mortality was
16% at one year. Complete (n  4) or partial (n  24) responses,
median 150 (range 42-600) days posttransplant, were associated
with time from diagnosis to HSCT, mismatched donor and
acute GVHD II-IV. Factors associated with survival included
chronic GVHD (hazards ratio, HR 4.12, P  .001), DLI (HR
3.39, P  .001), 3 metastatic sites (HR 2.61, P  .002) and a
Karnofsky score 	70 (HR 2.33, P  .03). Patients with chronic
GVHD and given DLI (n  17) had a 2-year survival of 70%.
Conclusions: Our data demonstrate that i) RCC patients with
less than 3 metastatic locations and a Karnofsky score 	70%
may be considered for HSCT, ii) RIC and allogeneic HSCT is
feasible in RCC patients with a low non-progression-mortality
(16%), iii) a clinically meaningful GVT effect can be generat-




GENE EXPRESSION ANALYSIS OF CIRCULATING HEMATOPOIETIC PRO-
GENITOR CELLS FROM IRRADIATED MICE AND HUMANS PROVIDES A
MOLECULAR PROFILE OF RADIATION INJURY
Chute, J.P., Muramoto, G., Dressman, H., Chao, N.J., Nevins, J. Duke
University, Durham, NC.
The risk for terrorist-mediated nuclear or radiological attack has
been identiﬁed as a major threat to the United States in the coming
decade. Radiation exposure can cause a spectrum of hematological
toxicities, from mild immunosuppression to myeloablation with
concordant life threatening complications. Accurate biological do-
simetry will be critical, therefore, for caregivers to triage individ-
uals to the appropriate medical management. Currently, biodosi-
metric tools include lymphocyte depletion kinetic and cytogenetic
analysis, both of which require several days for results to be ob-
tained. We propose that high throughput genomic analysis of
peripheral blood mononuclear cells (PB MNCs) can sensitively
identify patterns of molecular changes which occur following dif-
ferent levels of radiation exposure. In this study, we collected
primary PB MNCs from 10 week old C57Bl6 mice at 6 hours
following 4 different levels of radiation exposure: normal (non-
irradiated), 50 cGy (trivial exposure), 200 cGy (myelosuppressive)
and 1000 cGy (lethal). RNA was extracted and used for synthesis of
probes for hybridization to spotted arrays. We performed a binary
regression analysis to elucidate patterns of gene expression to
distinguish between a normal animal and one that had been ex-
posed to various levels of radiation. Distinct gene expression pat-
terns were evident within PB MNCs at each of the 4 exposure
levels, demonstrating the feasibility of this approach. We found
that the selected metagene pattern for “normal” was able to dis-
tinguish normal from 50 cGy, 200 cGy and 1000 cGy exposure
with 100% predictive capacity. The predictors selected for 50 cGy,
200 cGy and 1000 cGy were equally powerful at distinguishing
these levels of exposure from all others. These data demonstrate
the power of this approach to correctly distinguish clinically rele-
vant levels of radiation exposure. In order to validate these molec-
ular predictors generated in mice as proﬁles of human radiation
response, we are currently testing, in a blinded manner, whether
these predictors can distinguish different levels of radiation expo-
sure in human PB samples collected from patients who have un-
dergone 200 cGy or 1000 cGy total body irradiation. These vali-
dated biomarkers of radiation response can serve as templates for
rapid screening tests for radiation exposure and, more broadly, are
potential targets for therapeutic intervention.
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A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF VELAFERMIN
(CG53135-05) ADMINISTERED INTRAVENOUSLY AS A SINGLE DOSE
FOR THE PREVENTION OF ORAL MUCOSITIS IN PATIENTS RECEIVING
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT)
Anaissie, E.1, Schuster, M.W.2, Hurd, D.3, Bensinger, W.4, Mason, J.5,
McCarty, J.M.6, Rifkin, R.7, Maziarz, R.8, Bolwell, B.9, Mehta, J.10,
Mangan, K.11, Skikne, B.12, Abboud, C.13, Chao, N.14,
Stadtmauer, E.15, Fernandez, H.16, Lazarus, H.17, Westervelt, P.18,
Halvorsen, Y.19, Gerwien, R.19, Annino, V.19, Hahne, W.19 1University
of Arkansas; 2Weill Med College of Cornell University; 3Wake Forest
University; 4Fred Hutchinson Cancer Research; 5Scripps Green BMT
Program; 6Virginia Commonwealth University; 7Rocky Mountain Blood
and Marrow Transplant; 8Oregon Health & Science University; 9Cleve-
land Clinic Foundation; 10Northwestern University; 11Fox Chase, Tem-
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